Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Arcoxia

(Etoricoxib)

ApprovedSmall molecule

Etoricoxib is used to reduce pain and swelling from conditions like arthritis, gout, and other inflammatory diseases. It works by decreasing inflammation in the body to help relieve discomfort.[2] Arcoxia is currently approved and in use across 34 indications[4].[1]

Arcoxia is one of 675 small molecule programs targeting HIV infection. It is currently in Approved.

34

Indications

67

Total Trials

3

Active Trials

674

Competitors

Pipeline

Status by Indication[4][1]

Indication

HIV InfectionActive, not recruiting

Neuropathic PainActive, not recruiting

Low Back PainActive, not recruiting

Proliferative Diabetic RetinopathyActive, not recruiting

Wound HealingActive, not recruiting

ArthritisActive, not recruiting

Rheumatic DiseaseUnknown

Bone NeoplasmActive, not recruiting

DysmenorrheaActive, not recruiting

Hallux ValgusActive, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Neuropathic PainApproved

Active, not recruiting

Low Back PainPhase 3

Active, not recruiting

Proliferative Diabetic RetinopathyPreclinical

Active, not recruiting

Wound HealingApproved

Active, not recruiting

ArthritisPreclinical

Active, not recruiting

Rheumatic DiseasePreclinical

Unknown

Bone NeoplasmPhase 2

Active, not recruiting

DysmenorrheaPhase 3

Active, not recruiting

Hallux ValgusApproved

Active, not recruiting

Showing 10 of 31 indications

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Arcoxia

Novantrone

Mekinist

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Ranexa

MMenarini International Operations Luxembourg SA

Duragesic

Triptorelin Pamoate

Ifex

BBaxter Healthcare Corporation

Statin

Bristol-Myers Squibb

Prednisone or Prednisolone

Johnson & Johnson

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedNot yet recruiting

Gout

NCT07661030

Q4 2027

Phase 2Not yet recruiting

Parkinson

NCT07370532

Clinical

Trials by Indication[1]

Osteoarthritis5 trials

Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Completed·OOrganon and Co·Phase 4·NCT00757627·500 enrolled

Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis

Completed·OOrganon and Co·Phase 3·NCT01554163·239 enrolled

Pulse Shortwave Therapy in Cervical Osteoarthritis

Completed·BBioElectronics Corporation·N/A·NCT03542955·180 enrolled

Show 2 more trials

Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis

Completed·—·Phase 4·NCT00927004·80 enrolled

A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142)

Withdrawn·OOrganon and Co·Phase 4·NCT01429168

Total Knee Arthroplasty4 trials

Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty

Completed·FFoisor Orthopedics Clinical Hospital·N/A·NCT02534610·165 enrolled

Lornoxicam Versus Etoricoxib in Postoperative Pain After Total Knee Arthroplasty

Completed·FFoisor Orthopedics Clinical Hospital·Phase 3·NCT02750917·120 enrolled

Efficacy Study of Pre-emptive Etoricoxib for Postoperative Pain and Functional Outcome in Total Knee Arthroplasty

Completed·SSingapore General Hospital·Phase 2·NCT01246362·65 enrolled

Show 1 more trial

Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty

Completed·NNational University Hospital, Singapore·Phase 3·NCT02954484·116 enrolled

Rheumatoid Arthritis4 trials

A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)

Completed·OOrganon and Co·Phase 3·NCT01208181·1,404 enrolled

Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)

Completed·OOrganon and Co·Phase 2·NCT00264147·761 enrolled

Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)

Withdrawn·NNorthumbria Healthcare NHS Foundation Trust·Phase 4·NCT01067430

Show 1 more trial

Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis

Completed·—·Phase 4·NCT04144101·40 enrolled

Ankylosing Spondylitis3 trials

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

Completed·OOrganon and Co··NCT01327638·21,108 enrolled

Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs

Completed·SSpanish Foundation of Rheumatology·Phase 3·NCT01091675·58 enrolled

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Completed·OOrganon and Co··NCT01077843·27,381 enrolled

Laparoscopic Surgery2 trials

Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Surgery

Completed·UUllevaal University Hospital·Phase 3·NCT00373464·126 enrolled

Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery

Terminated·—·Phase 4·NCT00763685·40 enrolled

45 more indications

Arthritis2 trials

Oral Huzhang Granules for Acute Gouty Arthritis

Unknown status·SShanghai Yueyang Integrated Medicine Hospital·Phase 2·NCT04462666·267 enrolled

Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis

Completed·GGuangdong Provincial Hospital of Traditional Chinese Medicine·N/A·NCT06001112·76 enrolled

Headache2 trials

Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache

Unknown status·SShaare Zedek Medical Center·Phase 4·NCT00752921·200 enrolled

Trial of Etoricoxib (Arcoxia) Taken Prophylactically to Prevent Ramadan Headache

Completed·HHartford Hospital·Phase 4·NCT01148303·220 enrolled

Dysmenorrhea2 trials

An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)

Completed·OOrganon and Co·Phase 3·NCT00092729·129 enrolled

Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)

Completed·OOrganon and Co·Phase 3·NCT01462370·139 enrolled

Hallux valgus2 trials

A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain

Withdrawn·KKarolinska Institutet·Phase 4·NCT01190722

The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery

Completed·KKarolinska Institutet·Phase 4·NCT00733421·100 enrolled

Inflammation1 trial

Study of Etoricoxib for the Treatment of Muscle Pain and Inflammation Induced by Eccentric Exercise

Completed·XX-pert Med GmbH·Phase 1·NCT01271348·50 enrolled

Tendinopathy1 trial

"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"

Completed·AArgentine Tennis Association·Phase 4·NCT00792376·56 enrolled

Acute Pain1 trial

Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib

Completed·GGuangdong Provincial People's Hospital·Phase 2·NCT04565600·144 enrolled

Third Molar1 trial

Etoricoxib Versus Ibuprofen in Third Molar Extraction Pain

Unknown status·UUniversita di Verona·Phase 4·NCT00855777·110 enrolled

Celecoxib1 trial

Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol

Completed·TTurku University Hospital·Phase 1·NCT01304069·12 enrolled

Vaccination1 trial

Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients

Completed·DDag Kvale·Phase 2·NCT01269515·60 enrolled

Tuberculosis1 trial

Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic

Completed·AAnne Margarita Dyrhol Riise·Phase 1·NCT02503839·39 enrolled

Radius Fracture1 trial

Rebound Pain After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block

Completed·OOslo University Hospital·Phase 3·NCT03011905·53 enrolled

Fibromyalgia1 trial

Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia

Unknown status·MMeir Medical Center·Phase 4·NCT00755521·80 enrolled

Allergic Asthma1 trial

COX-2 Inhibition in Allergic Asthma

Completed·BBarbro Dahlen·N/A·NCT01002690·16 enrolled

Low back pain1 trial

Evaluation of the Efficacy and Tolerability of Etoricoxib Monotherapy Versus Combination Oxycodone-etoricoxib in Moderate to Severe Pain From Chronic Low Back Pain

Unknown status·AAzienda Sanitaria Locale 4, Teramo·Phase 4·NCT01344720·250 enrolled

Periodontitis1 trial

EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).

Completed·TTatyasaheb Kore Dental College·Phase 4·NCT02149758·40 enrolled

Hyperalgesia1 trial

Efficacy of Etoricoxib on Peripheral Hyperalgesia

Terminated·RRuhr University of Bochum·Phase 2·NCT01088256·9 enrolled

Coagulation1 trial

Analgesic Effect of Etoricoxib (ARCOXIA®) 120MG During Retinal Laser Photocoagulation

Completed·UUniversity of Sao Paulo·N/A·NCT00529594·44 enrolled

Heterotopic Ossification1 trial

Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement

Completed·RRadboud University Medical Center·Phase 4·NCT01022190·42 enrolled

Adult Subject1 trial

Bioequivalence Study of Etoricoxib in Healthy Adult Subjects Under Fasting Condition

Completed·FFuture University in Egypt·Phase 1·NCT05532280·30 enrolled

Inflammatory Response1 trial

Modulation of the Surgical Inflammatory Response by Etoricoxib

Terminated·UUniversity of Erlangen-Nürnberg Medical School·Phase 2·NCT00746720·23 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions

Unknown status·PPharmtechnology LLC·Phase 1·NCT04830579·34 enrolled

Knee Replacement Surgery1 trial

Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)

Completed·OOrganon and Co·Phase 3·NCT00820027·776 enrolled

Wound Healing1 trial

Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery

Completed·UUniversity of Belgrade·Phase 4·NCT05791721·90 enrolled

Adverse Effect1 trial

Serum Creatinine Change / Renal Adverse Effect With Use of Non-steroidal Painkillers in Axial Spondyloarthritis Patients

Completed·—·Phase 4·NCT03582332·64 enrolled

Pregabalin1 trial

The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination

Not yet recruiting·MMuhammad Ilyas·Phase 4·NCT06401499·140 enrolled

TED1 trial

Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets

Completed·DDexa Medica Group·N/A·NCT03422575·26 enrolled

Hysterectomy1 trial

A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00788710·430 enrolled

Dexamethasone1 trial

Comparison of the Anti-Inflammatory Efficacy of Preemptive Dexamethasone and Etoricoxib

Unknown status·—·Phase 1·NCT05142098·170 enrolled

Acute1 trial

Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

Terminated·CClinica Virgen Milagrosa·Phase 3·NCT00876317·45 enrolled

Analgesic Efficacy1 trial

Biomarkers for Prediction of Analgesic Efficacy in Knee OA.

Completed·RRambam Health Care Campus·N/A·NCT05256342·17 enrolled

Laparoscopy1 trial

Pain Post Abdominal Laparoscopy Prevention With Arcoxia

Completed·—·Phase 4·NCT00565682·60 enrolled

Post Operative Pain1 trial

Etoricoxib for Postoperative Pain After Thyroid Surgery

Unknown status·—·Phase 4·NCT00935116·70 enrolled

Tooth Sensitivity1 trial

Effect of an Anti-inflammatory on Tooth Sensitivity Caused by Bleaching

Completed·EEloisa Andrade de Paula·N/A·NCT01300780·30 enrolled

Prostate Cancer1 trial

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT00427999·67 enrolled

Adverse Events1 trial

Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)

Completed·OOrganon and Co··NCT01685424·79,189 enrolled

Prostatectomy1 trial

Etoricoxib With Flavoxate for Reducing Morphine Requirement After Transurethral Prostatectomy (TURP)

Completed·MMahidol University·Phase 4·NCT00440739·128 enrolled

Inguinal hernia1 trial

Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor

Completed·—·N/A·NCT02884986·60 enrolled

Parkinson1 trial

Etoricoxib in Patients With Parkinsonian Disease

Not yet recruiting·IIhab Elsayed Hassan·Phase 2·NCT07370532·60 enrolled

Hip Arthroplasty1 trial

Dexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty

Completed·KKuopio University Hospital·Phase 4·NCT02568735·24 enrolled

Total Hip Arthroplasty1 trial

Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty

Completed·UUniversity of Regensburg·Phase 3·NCT01229774·100 enrolled

Neuropathic Pain1 trial

Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain

Unknown status·AAnalgesic Solutions·Phase 4·NCT01264237·120 enrolled

Analgesia1 trial

Preemptive Analgesia in Cruciate Reconstruction

Completed·PPrince of Songkla University·Phase 3·NCT01017380·30 enrolled

Gout1 trial

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time: A Multicenter, Randomized, Parallel-Controlled Study

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Approved·NCT07661030·142 enrolled

Unspecified1 trial

Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

Completed·OOrganon and Co·Phase 1·NCT00945035·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 67 trial records for Etoricoxib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Arcoxia drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Etoricoxib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Etoricoxib. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cyclooxygenase-2 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Related News